Cell Technologies is advancing clinical assets using our proprietary AI platforms. Chondrostem is projected to be the first AI delveloped FDA approved therapy in the market.
Oracle and Delfi systematize the high-risk decisions — cell type selection, manufacturing release criteria, trial design, regulatory strategy — that kill more than 90% of drug development programs. We don't optimize for benchmarks; we optimize for go/no-go decisions.
Published Phase 1/2 results show 60% pain reduction at 12 months in knee osteoarthritis, 90% disc regeneration on MRI, and 80% independent opioid cessation in back pain patients — across more than a decade of clinical and translational research.
Osteoarthritis and degenerative disc disease together affect more than 600 million people globally, with no approved disease-modifying therapies. The broader regenerative medicine market is projected to exceed $66B by 2030.
Most AI pharmas focus on one modality. Our AI platforms span both cell therapy (Oracle) and biologics R&D (Delfi) — giving us optionality across modalities as our pipeline expands, with shared intelligence and a unified development ontology.
Our proprietary technology is protected by six issued patents and supported by multiple peer-reviewed publications. We hold FDA and Health Canada approvals for our core platforms — with Exclusive Market Authorization (EMA) under pursuit in Canada.
Every preclinical asset runs end-to-end through Oracle and Delfi before any laboratory investment, materially reducing the cost and time-to-decision per program. Our model is built for capital efficiency through every phase.
Regenerative medicine is one of the fastest-growing areas in pharmaceuticals, attracting active investment from major players including Astellas, Johnson & Johnson, and Fujifilm. Cell Technologies sits at the intersection of this growth and the broader pharmaceutical R&D opportunity unlocked by AI.
SOURCES: ARK INVEST REGEN MED REPORT 2025 · BCG BIOPHARMA TRENDS 2026 · BIO INDUSTRY OUTLOOK · INTERNAL ANALYSIS
For investor presentations, financial updates, and strategic partnership discussions, please contact our investor relations team. We share materials on request with qualified investors.